VCEL vs TGTX Comparison

Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.